search
Back to results

Vitamin D Supplementation D_SAF Pilot Study

Primary Purpose

Vitamin D Deficiency

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
25,000 IU
50,000 IU
Placebo
Sponsored by
University of Surrey
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Vitamin D Deficiency

Eligibility Criteria

16 Years - 32 Years (Child, Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • RM recruit troops commencing training during the winter and summer months,
  • aged between 16 - 32 years at the Start of Training
  • having successfully completed the physical and professional selection tests which comprise the Potential Royal Marine Course (PRMC)
  • be deemed medically fit and healthy following medical screening at the AFCO and again at CTC if required

Exclusion Criteria:

  • not participating in Recruit Syllabus (RS10) for RM recruit training
  • deemed unsuitable by the IMO or the training team

Sites / Locations

  • University of Surrey
  • Institute of Naval Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

25,000 IU

50,000 IU

Placebo

Arm Description

Outcomes

Primary Outcome Measures

The dose-response changes in 25-hydroxyvitamin D
The incidence of injury/illness in recruits during training

Secondary Outcome Measures

Full Information

First Posted
July 23, 2019
Last Updated
July 25, 2019
Sponsor
University of Surrey
Collaborators
Institute of Naval Medicine, CTRM Lympstone, Navy Command Headquarters
search

1. Study Identification

Unique Protocol Identification Number
NCT04033796
Brief Title
Vitamin D Supplementation D_SAF Pilot Study
Official Title
Vitamin D Supplementation in the Armed Forces (D_SAF) PILOT STUDY
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
December 1, 2014 (Actual)
Primary Completion Date
June 10, 2016 (Actual)
Study Completion Date
June 10, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Surrey
Collaborators
Institute of Naval Medicine, CTRM Lympstone, Navy Command Headquarters

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study is a randomised control trial (RCT) pilot study to determine the appropriate vitamin D dose for the main study. The pilot study includes three matched groups, which will form two vitamin D supplementation groups (at 25,000 IU and 50,000 IU every two months), and a third placebo supplementation group. The aim was to develop an appropriate supplementation regimen that was compatible with recruit training and maintained serum vitamin D (25OHD) status above 50 nmol/l during recruit training.
Detailed Description
Study Overview: Aim: The dose-response to vitamin D3 supplementation in Royal Marine recruits undertaking military training. Part-A of this research project will provide a pilot study for the main study. Volunteer recruits will initially complete a healthy history, smoking habit and alcohol consumption questionnaire. Height, body mass (from which BMI will be calculated), and calf girth/skinfold will be measured. A 20 ml blood sample will be drawn in two parts: a 15 ml blood sample (gold top serum vacutainers) for determination of vitamin D status, calcium and albumin concentrations, PTH levels, serum collagen type I cross-linked C-telopeptide (CTx), carboxy-terminal propeptide of type I collagen (P1NP), ferritin (Fe) and antibody responses against S. aureus or other antigens; and a 5 ml blood sample (white top EDTA plasma vacutainers) will be drawn for determination of plasma cytokine levels. At one sample point only, DNA will be extracted from the cell pellet acquired following centrifuging of the whole blood to separate the plasma. This DNA will be analysed for the specific single nucleotide polymorphisms (SNPs) that have been shown to be associated with vitamin D metabolism. Permission will also be sought to collate the outcome of the week-1 and week-9 Royal Marine Fitness Assessment (RMFA). The pilot study recruit cohort will be randomised into one of three groups: (i) a vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to ~400 IU.d-1); (ii) a vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to ~800 IU.d-1); and (iii) a placebo (administered orally every two months) supplementation control group. The vitamin D and placebo supplements will be manufactured by Pharmaterials Ltd., Unit B, 5 Boulton Road, Reading, RG2 0NH, UK. Both the active and placebo supplements will be presented as identical (size and appearance) tablets, indiscernible from each other for either the volunteer or the study team in situ at CTC. All three groups will receive one tablet at each time point. Recruits will be randomly assigned to a study group, but the three groups will be matched for age, height, body mass and aerobic fitness. Randomisation of supplement/placebo administration to study volunteers will be undertaken by Statisticians from the University of Surrey. Study team staff will monitor supplement taking and will further confirm supplement taking through exit interviews. Further 20 ml blood samples will be drawn every two months (i.e. at weeks 8, 16 and 32 of RM training), and the smoking habit and alcohol consumption questionnaire will be readministered. The Food Frequency Questionnaire (FFQ)25,26 will be administered in week- 6 of training; this will allow the recruits' habitual RM training diet to be established following the civilian to military transition. Permission will be sought to collate the outcome of the week-1 and week-9 Royal Marine Fitness Assessment (RMFA). Permission will also be sought to prospectively collate data from the Defence Medical Information Capability Programme (DMICP) system describing the prevalence of injury and illness in study volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
532 (Actual)

8. Arms, Groups, and Interventions

Arm Title
25,000 IU
Arm Type
Active Comparator
Arm Title
50,000 IU
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
25,000 IU
Intervention Description
Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to ~400 IU/d);
Intervention Type
Dietary Supplement
Intervention Name(s)
50,000 IU
Intervention Description
Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to ~800 IU/d);
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
A placebo (administered orally every two months) supplementation control group.
Primary Outcome Measure Information:
Title
The dose-response changes in 25-hydroxyvitamin D
Time Frame
32 weeks
Title
The incidence of injury/illness in recruits during training
Time Frame
32 weeks

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
32 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: RM recruit troops commencing training during the winter and summer months, aged between 16 - 32 years at the Start of Training having successfully completed the physical and professional selection tests which comprise the Potential Royal Marine Course (PRMC) be deemed medically fit and healthy following medical screening at the AFCO and again at CTC if required Exclusion Criteria: not participating in Recruit Syllabus (RS10) for RM recruit training deemed unsuitable by the IMO or the training team
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joanne L Fallowfield, PhD
Organizational Affiliation
Institute of Naval Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Susan A Lanham-New, Professor
Organizational Affiliation
University of Surrey
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Surrey
City
Guildford
State/Province
Surrey
ZIP/Postal Code
GU2 7XH
Country
United Kingdom
Facility Name
Institute of Naval Medicine
City
Gosport
ZIP/Postal Code
PO12 2DL
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Vitamin D Supplementation D_SAF Pilot Study

We'll reach out to this number within 24 hrs